AnaptysBio announced Phase 2b trial data for rosnilimab in rheumatoid arthritis accepted for presentation at ACR Convergence 2025.
Quiver AI Summary
AnaptysBio, Inc. has announced that the complete data from its Phase 2b trial of rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis, has been accepted for a late-breaking oral presentation at the American College of Rheumatology Convergence 2025 conference in Chicago from October 24-29, 2025. Paul Lizzul, the company's chief medical officer, highlighted the promising safety and efficacy profile of rosnilimab, which demonstrated a durable therapeutic effect for at least three months after treatment cessation. The presentation, led by Professor Paul Emery from the University of Leeds, will detail rosnilimab's ability to selectively target and deplete pathogenic T cells involved in autoimmune diseases while preserving nonpathogenic T cells. AnaptysBio is a clinical-stage biotechnology firm focused on innovative immunology therapeutics and has plans to separate its biopharma operations from its royalty assets by the end of 2026.
Potential Positives
- Complete data from the Phase 2b trial of rosnilimab in rheumatoid arthritis is set for a late-breaking oral presentation at a prominent medical conference, ACR Convergence 2025, highlighting the significance of the research.
- The acceptance of the trial data presentation underscores the transformational potential of rosnilimab, which has shown a compelling safety and tolerability profile along with durable efficacy.
- AnaptysBio continues to advance its clinical pipeline with multiple ongoing trials, including rosnilimab for ulcerative colitis and other innovative therapeutic candidates, suggesting a robust development strategy in immunology therapeutics.
Potential Negatives
- While the company announced advanced data for rosnilimab, it does not provide any new data on its efficacy or safety compared to previous announcements, which may lead to concerns about a lack of significant progress in clinical results.
- The separation of biopharma operations from royalty assets suggests a need to realign focus, which may indicate that the company is not fully confident in its current product pipeline or business strategy.
FAQ
What is rosnilimab and its purpose in rheumatoid arthritis treatment?
Rosnilimab is a novel therapeutic antibody designed to selectively deplete pathogenic T cells, targeting those involved in rheumatoid arthritis.
When will the Phase 2b trial data for rosnilimab be presented?
The complete data will be presented on Wednesday, October 29, 2025, from 8:00am to 9:30am CT.
Who will be presenting the rosnilimab data at ACR Convergence 2025?
Professor Paul Emery, M.D., from the University of Leeds, will be the presenting author for the rosnilimab data.
What were the key findings from the Phase 2b trial of rosnilimab?
The trial showed a compelling safety and tolerability profile, with JAK-like efficacy lasting for at least three months off-drug.
Where can I access the presentation after it is delivered?
The presentation will be available for download on the Anaptys website following the session.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- HOLLINGS RENTON has made 0 purchases and 5 sales selling 34,171 shares for an estimated $766,173.
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) sold 8,240 shares for an estimated $238,960
- DENNIS M FENTON sold 3,015 shares for an estimated $72,269
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 70 institutional investors add shares of $ANAB stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 1,833,035 shares (-96.2%) from their portfolio in Q2 2025, for an estimated $40,693,377
- MORGAN STANLEY added 1,365,204 shares (+270.5%) to their portfolio in Q2 2025, for an estimated $30,307,528
- BOXER CAPITAL MANAGEMENT, LLC removed 1,300,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,860,000
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 1,094,009 shares (-23.6%) from their portfolio in Q2 2025, for an estimated $24,286,999
- ASSENAGON ASSET MANAGEMENT S.A. added 822,975 shares (+4852.7%) to their portfolio in Q3 2025, for an estimated $25,199,494
- UBS GROUP AG added 782,226 shares (+159.5%) to their portfolio in Q2 2025, for an estimated $17,365,417
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 772,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $17,138,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANAB Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/13/2025
- Wedbush issued a "Outperform" rating on 09/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/30/2025
- JP Morgan issued a "Overweight" rating on 07/24/2025
- Guggenheim issued a "Buy" rating on 05/28/2025
To track analyst ratings and price targets for $ANAB, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 6 analysts offer price targets for $ANAB in the last 6 months, with a median target of $68.5.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $78.0 on 10/13/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $59.0 on 09/30/2025
- Martin Fan from Wedbush set a target price of $45.0 on 09/30/2025
- Eliana Merle from UBS set a target price of $20.0 on 08/12/2025
- Anupam Rama from JP Morgan set a target price of $80.0 on 07/24/2025
- Yatin Suneja from Guggenheim set a target price of $90.0 on 05/28/2025
Full Release
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025.
“We are honored to be selected by ACR to present our late-breaking Phase 2b data for rosnilimab in RA,” said Paul Lizzul, chief medical officer of Anaptys. “Being selected reinforces the transformational potential of rosnilimab, which delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that was durable for at least three months off-drug. We look forward to Professor Emery’s presentation later this month.”
Presentation Details:
- Abstract Title – Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2b Trial
- Abstract ID - 2215555
-
Session Date and Time
- Wednesday, Oct. 29 from 8:00am – 9:30am CT
Paul Emery, M.D., professor, Rheumatology, University of Leeds, Leeds Biomedical Research Centre, U.K., will be the presenting author.
The presentation will be available for download on the Anaptys website after the session here .
About Rosnilimab
Rosnilimab is a novel therapeutic antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. When activated, these T cells proliferate and migrate and secrete inflammatory cytokines that are the drivers of autoimmune and inflammatory diseases.
Rosnilimab is designed to selectively and potently deplete pathogenic T cells in both inflamed tissue and the periphery while sparing nonpathogenic T cells, including naïve T cells, to preserve overall immune function and restore immune homeostasis. This drives specific immunological outcomes, such as a reduction in T cell proliferation, migration and cytokine secretion, and a reduction of plasma cell generation and autoantibody levels.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist ( Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here .
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
